BullFrog AI Holdings, Inc. Logo

BullFrog AI Holdings, Inc.

Leverages causal AI to accelerate drug discovery and identify novel targets for biopharmaceuticals.

BFRG | US

Overview

Corporate Details

ISIN(s):
US12021E1091
LEI:
Country:
United States of America
Address:
325 ELLINGTON BLVD., 20878 GAITHERSBURG
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

BullFrog AI Holdings, Inc. is a technology-enabled biopharmaceutical company that leverages artificial intelligence (AI) and machine learning (ML) to enhance the drug discovery and development process. The company utilizes a proprietary platform featuring causal AI and graph-based analytics to model complex biological systems. This technology enables the rapid and cost-effective identification and validation of novel drug targets, aiming to generate actionable insights from complex data. By supporting both internal and external drug development programs, BullFrog AI's mission is to accelerate research, lower costs, and significantly improve the success rate of bringing new therapeutics to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BullFrog AI Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BullFrog AI Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BullFrog AI Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium
CYAD
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom
CWR

Talk to a Data Expert

Have a question? We'll get back to you promptly.